JP2020536488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536488A5 JP2020536488A5 JP2020505360A JP2020505360A JP2020536488A5 JP 2020536488 A5 JP2020536488 A5 JP 2020536488A5 JP 2020505360 A JP2020505360 A JP 2020505360A JP 2020505360 A JP2020505360 A JP 2020505360A JP 2020536488 A5 JP2020536488 A5 JP 2020536488A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 77
- 108090000765 processed proteins & peptides Proteins 0.000 claims 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims 77
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 102000044459 human CD47 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540118P | 2017-08-02 | 2017-08-02 | |
| US62/540,118 | 2017-08-02 | ||
| US201862657094P | 2018-04-13 | 2018-04-13 | |
| US62/657,094 | 2018-04-13 | ||
| PCT/US2018/044384 WO2019027903A1 (en) | 2017-08-02 | 2018-07-30 | ANTI-CD47 ANTIBODIES AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536488A JP2020536488A (ja) | 2020-12-17 |
| JP2020536488A5 true JP2020536488A5 (enExample) | 2021-07-26 |
| JP7262440B2 JP7262440B2 (ja) | 2023-04-21 |
Family
ID=65233054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505360A Active JP7262440B2 (ja) | 2017-08-02 | 2018-07-30 | 抗ｃｄ４７抗体及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11401329B2 (enExample) |
| EP (1) | EP3661965A4 (enExample) |
| JP (1) | JP7262440B2 (enExample) |
| KR (1) | KR102646468B1 (enExample) |
| CN (1) | CN111183155B (enExample) |
| AU (1) | AU2018312222B2 (enExample) |
| BR (1) | BR112020001679A2 (enExample) |
| CA (1) | CA3071860A1 (enExample) |
| IL (1) | IL272330B2 (enExample) |
| MX (1) | MX2020001309A (enExample) |
| NZ (1) | NZ761568A (enExample) |
| SG (1) | SG11202000053TA (enExample) |
| WO (1) | WO2019027903A1 (enExample) |
| ZA (1) | ZA202000373B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831759B (zh) | 2017-12-01 | 2024-02-11 | 美商思進公司 | Cd47抗體及其用於治療癌症之用途 |
| WO2019217145A1 (en) | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| WO2020215012A1 (en) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Antibodies that target human cd47 |
| AU2020296785A1 (en) * | 2019-06-19 | 2022-01-20 | Lepu Biopharma Co., Ltd. | Anti-CD47 antibodies and uses thereof |
| WO2021003082A1 (en) * | 2019-07-03 | 2021-01-07 | Phanes Therapeutics, Inc. | Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof |
| US20220332848A1 (en) * | 2019-07-16 | 2022-10-20 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-ctla-4 bispecific antibody and preparation method therefor and application thereof |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
| KR102902719B1 (ko) | 2019-10-18 | 2025-12-24 | 포티 세븐, 엘엘씨 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4061420A1 (en) * | 2019-11-20 | 2022-09-28 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| EP4077377A4 (en) * | 2019-12-17 | 2024-07-03 | Phanes Therapeutics, Inc. | BISPECIFIC ANTIBODIES WITH ALTERNATING INTERCHAIN CYSTEINES AND USES THEREOF |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| TWI869582B (zh) * | 2020-04-10 | 2025-01-11 | 大陸商和記黃埔醫藥（上海）有限公司 | 抗ｃｄ４７抗體及其用途 |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| AU2021380853B2 (en) * | 2020-12-23 | 2024-10-10 | Guangdong Feipeng Pharmaceutical Co., Ltd. | Antibody targeting CD47 and application thereof |
| BR112023016713A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US20250129155A1 (en) * | 2021-06-30 | 2025-04-24 | Innobation Bio Co., Ltd. | Humanized antibody specific for cd47 and pharmaceutical composition for preventing or treating cd47-related diseases comprising the same |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| KR20250036855A (ko) | 2022-07-12 | 2025-03-14 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120025427A (zh) * | 2023-11-23 | 2025-05-23 | 东莞市朋志生物科技有限公司 | 一种抗甲型肝炎病毒的抗体及其应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025151607A1 (en) * | 2024-01-10 | 2025-07-17 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026089992A1 (en) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120427902B (zh) * | 2025-07-04 | 2025-09-12 | 杭州华得森生物技术有限公司 | 链霉亲和素偶联抗体捕获ctc检测试剂盒 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1997027873A1 (en) | 1996-01-30 | 1997-08-07 | Brigham & Women's Hospital, Inc. | Antibodies for modulating cd47-mediated neutrophil transmigration |
| DE19952960A1 (de) | 1999-11-03 | 2001-05-10 | Mark Andre Freyberg | Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| AU2002315052A1 (en) | 2001-05-15 | 2002-11-25 | Emory University | Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47 |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| CA2545166A1 (en) | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| WO2007033221A2 (en) | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| US20080131431A1 (en) | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| AU2007319576B2 (en) | 2006-10-06 | 2014-01-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
| EP2573112A1 (en) | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CN102257001A (zh) | 2008-12-19 | 2011-11-23 | 诺瓦提斯公司 | 治疗自体免疫和炎性病症的可溶性多肽 |
| WO2010083253A2 (en) | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| EP4311863A3 (en) | 2009-05-15 | 2024-04-10 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011042548A1 (en) * | 2009-10-09 | 2011-04-14 | Sanofi-Aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| JP2013514795A (ja) * | 2009-12-22 | 2013-05-02 | ノバルティス アーゲー | 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質 |
| US20110206696A1 (en) | 2010-01-25 | 2011-08-25 | The Washington University | Methods for inhibiting bone loss and bone metastasis |
| EP4349868A3 (en) | 2010-05-14 | 2024-08-28 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| WO2012031273A2 (en) * | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
| US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
| JP2014519338A (ja) | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
| FR2977587B1 (fr) | 2011-07-08 | 2013-08-30 | Univ Reims Champagne Ardenne | Peptide antagoniste de la liaison entre le cd47 et une proteine appartenant a la famille des thrombospondines |
| GB201200563D0 (en) | 2012-01-13 | 2012-02-29 | Imp Innovations Ltd | Binding molecule |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EA034778B1 (ru) | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Антитела к cd47 и способы их применения |
| US20140127269A1 (en) | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| WO2014078373A1 (en) * | 2012-11-13 | 2014-05-22 | Iogenetics, Llc | Antimicrobial compositions |
| EP4706769A2 (en) | 2012-12-03 | 2026-03-11 | NovImmune SA | Anti-cd47 antibodies and methods of use thereof |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| HRP20192013T1 (hr) | 2012-12-17 | 2020-02-07 | Trillium Therapeutics Inc. | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| CA2900256C (en) | 2013-02-05 | 2023-03-21 | Kim J. HASENKRUG | Cd47 targeted therapies for the treatment of infectious disease |
| JP2016507555A (ja) * | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| EP2992089B1 (en) | 2013-04-29 | 2021-09-08 | The Board of Trustees of the Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| AU2015204766B2 (en) | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN106459218B (zh) | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术（上海）有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
| ES2811274T3 (es) | 2014-04-18 | 2021-03-11 | Univ Leland Stanford Junior | Anticuerpos monoclonales humanizados y quiméricos para CD99 |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| DK3180363T3 (da) | 2014-08-15 | 2019-11-04 | Merck Patent Gmbh | Sirp-alpha-immunoglobulin fusionsproteiner |
| DK3656869T4 (da) | 2014-08-26 | 2025-05-19 | Univ Leland Stanford Junior | Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering |
| ES2822561T3 (es) | 2014-09-15 | 2021-05-04 | Univ Leland Stanford Junior | Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis |
| WO2016065329A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| MX2017006485A (es) * | 2014-11-18 | 2018-03-23 | Janssen Pharmaceutica Nv | Anticuerpos anti-cd47, metodos y usos. |
| FI3850946T3 (fi) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
| WO2016109415A1 (en) * | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| AU2016209268B2 (en) | 2015-01-21 | 2021-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| ES2838925T3 (es) | 2015-02-27 | 2021-07-02 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| TWI843184B (zh) | 2015-03-04 | 2024-05-21 | 南韓商柳韓洋行股份有限公司 | 結合cd47之抗體治療劑 |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| US9845345B2 (en) | 2015-05-18 | 2017-12-19 | Ab Initio Biotherapeutics, Inc. | SIRP polypeptide compositions and methods of use |
| WO2017049251A2 (en) | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| HK1257309A1 (zh) * | 2015-09-21 | 2019-10-18 | Erasmus University Medical Center | 抗-cd47抗体及使用方法 |
| ES2796378T3 (es) * | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| EP3443010B1 (en) | 2016-04-14 | 2024-08-07 | Ose Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| EP3481862A4 (en) | 2016-07-06 | 2020-08-12 | Celgene Corporation | LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3411071A4 (en) | 2016-10-20 | 2019-08-28 | I-Mab | NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
-
2018
- 2018-07-30 US US16/633,730 patent/US11401329B2/en active Active
- 2018-07-30 EP EP18840724.1A patent/EP3661965A4/en active Pending
- 2018-07-30 NZ NZ761568A patent/NZ761568A/en unknown
- 2018-07-30 SG SG11202000053TA patent/SG11202000053TA/en unknown
- 2018-07-30 KR KR1020207006052A patent/KR102646468B1/ko active Active
- 2018-07-30 AU AU2018312222A patent/AU2018312222B2/en active Active
- 2018-07-30 CN CN201880050597.7A patent/CN111183155B/zh active Active
- 2018-07-30 MX MX2020001309A patent/MX2020001309A/es unknown
- 2018-07-30 CA CA3071860A patent/CA3071860A1/en active Pending
- 2018-07-30 JP JP2020505360A patent/JP7262440B2/ja active Active
- 2018-07-30 WO PCT/US2018/044384 patent/WO2019027903A1/en not_active Ceased
- 2018-07-30 BR BR112020001679-9A patent/BR112020001679A2/pt unknown
- 2018-07-30 IL IL272330A patent/IL272330B2/en unknown
-
2020
- 2020-01-20 ZA ZA2020/00373A patent/ZA202000373B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500916A5 (enExample) | ||
| RU2019132843A (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| JP2021184710A (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| EP2890711B1 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
| JP2021516057A5 (enExample) | ||
| IL315837A (en) | Anti-SIRP-alpha antibodies | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| JP2018536393A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| RU2012127381A (ru) | Гуманизированные антитела против il-10 для лечения системной красной волчанки (sle) | |
| JP2012143232A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2021517459A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| JP2019520034A5 (enExample) | ||
| US20250145705A1 (en) | Gprc5d antibody and application thereof | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| CN116554323B (zh) | 人源化抗il21抗体的开发和应用 | |
| RU2020121996A (ru) | Материалы и способы, в том числе для выбора пола | |
| JP2021505191A5 (enExample) | ||
| CN117551200A (zh) | 一种抗人cd45抗体或其抗原结合片段及其制备方法 | |
| RU2018129180A (ru) | Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение | |
| JPWO2020004490A5 (enExample) |